PTT 2002.

Methods	Design: single‐center randomized controlled trial Setting: 1 center in Turkey Patient recruitment: June 1997 to September 1998 Blinding: none Intention‐to‐treat: unclear Follow‐up period: 6 months Lost to follow‐up: 0
Participants	Number randomized: statin 79, control 85 Mean age (SD) in years: statin 53 (11), control 52 (10) Men, n (%): statin 65 (82%), control 69 (81%) Diabetes, n (%): statin 14 (18%), control 13 (15%) Hypertension, n (%): statin 16 (20%), control 21 (25%) Current smoker, n (%): statin 63 (80%), control 66 (78%) Prior myocardial infarction, n (%): statin none, control none Index event, n (%): Myocardial infarction: statin 79 (100%), control 85 (100%) Unstable angina: none Fibrinolysis therapy: statin 79 (100%), control 85 (100%) Percutaneous coronary intervention (PCI): none Inclusion criteria: patients receiving fibrinolysis therapy within 6 hours of ST‐segment elevated acute MI Exclusion criteria: contraindications for thrombolytic therapy, age > 75 years, history of myocardial infarction, previous percutaneous transluminal coronary angioplasty, coronary artery bypass graft surgery, congestive heart failure, secondary hyperlipidemia, uncontrolled hypertension or diabetes mellitus, liver disease, thyroid dysfunction, use of anticoagulant drugs other than aspirin, use of steroids or hormone replacement therapy, women of childbearing potential and patients with physical or psychosocial disorders that could interfere with protocol adherence
Interventions	Pravastatin 40 mg/d
Outcomes	Primary: composite of death, non‐fatal MI, and non‐fatal stroke, death from any cause, cardiovascular death, fatal MI, non‐fatal MI, total stroke, revascularization procedures (CABG/PCI), "recurrent angina pectoris"
Source	Not funded
Daily intervention	All patients received fibrinolysis therapy, intravenous nitrates, heparin infusions, a AHA step II diet and a daily 100 mg aspirin
Control	Usual care
Notes	Outcome data available at 1 and 6 months. Note: only a subgroup of 77 patients (40 intervention, 37 control, those who received additional coronary angioplasty) were followed up for 6 months
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Sequence generation unspecified
Allocation concealment (selection bias)	Unclear risk	Unreported
Blinding (performance bias and detection bias) All outcomes	High risk	No blinding of participants, caregivers, or clinical outcome assessors
Incomplete outcome data (attrition bias) All outcomes	Low risk	Complete follow‐up for clinical outcomes
Selective reporting (reporting bias)	Low risk	Author contact established; data on relevant outcomes provided
Other bias	Unclear risk	Adherence to the intention‐to‐treat principle not reported